FuturedMe was launched based on “CANDDY™” an original technology of drug design developed by Tokyo University of Science. CANDDY™ compounds induce degradation, NOT inhibition of the targets related diseases. FuturedMe brings CHANGE to you with “Future medicine”.
Our mission is to bring each medicine to each patient who do not have any medicine (No Patients without Medicine™). Nowadays you know genes related your disease with gene panels as a diagnosis, however, 20-30% of you do NOT have any specific medicines. Our goal is to bring each medicine to every single patient. We change undruggable target to druggable one with CANDDY™ technology.
FuturedMe is a pioneer in the science of using CANDDY™ Platform—new protein degradation platform—to make new small molecules as drug candidates. CANDDY™ technology has invented by Tokyo University of Science, professor Etsuko Miyamoto-Sato. CANDDY™ is a ubiquitin-INDEPENDENT and direct proteasomal degradation technology, which can break down proteins of interest using the cell’s natural protein degradation machinery rather than merely inhibiting the function of the proteins, as traditional drugs do. The benefit is versatility and flexibility in more simply designing and profiling. CANDDY™ is a technology that would release any patients from their agonies and delivering healthy life.
| Registered Name | FuturedMe Inc. |
|---|---|
| Date of Establishment | June 26th, 2018 |
| Number of Employees | 8 (including 3 Ph.D. as of May 2023) |
| Location | Head Office / 2-3-11, Nihonbashi Honcho, Chuo-ku, Tokyo Japan Research Laboratories / 5-4-6, Kashiwanoha, Kashiwa, Chiba Japan |
| Directors |
|
| Our Bank | Mizuho Bank, Ltd. |
|---|